Učitavanje...
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
BACKGROUND: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster head...
Spremljeno u:
| Izdano u: | Ther Adv Neurol Disord |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7222235/ https://ncbi.nlm.nih.gov/pubmed/32426040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420918088 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|